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doi:10.1016/j.ejvs.2009.08.006Abstract Objective: Endovascular repair (EVAR) of abdominal aortic aneurysms (AAAs) has led
to a reduction in the perioperativemortalitywhen comparedwith open repair. However, re-inter-
vention forcomplications, suchasendoleak,mayberequired inupto20%of thecases.Controversy
exists over the management of Type 2 endoleaks. This study examined the outcomes of patients
with Type 2 endoleaks treated conservatively to inform the ongoing management debate.
Methods: All patients with a confirmed Type 2 endoleak after EVAR for an infrarenal AAA were
included in the study. Data regarding device details, endoleak and time point, aneurysm sac
growth, interventionandoutcomewerecollected retrospectively fromcasenotesand thevascular
research database.
Results: Forty-oneType2endoleakswere seen in369EVARsperformedfor infrarenalAAAbetween
March1994andJune2006.Twenty-fivewere isolatedType2endoleaksand16occurred inconjunc-
tionwith other endoleaks. Of the 25 isolated Type 2 endoleaks, 18 (72%) patients demonstrated no
increase in sac size, six (24%)patients showedanenlargementof thesacandonepatientwas lost to
follow-up. Only one patient underwent intervention for an isolated Type 2 endoleak. After amean
follow-up period of 4 years, approximately half of the patients (48%) remain under observation
(with an enlarging or stable sac), whilst the others (48%) have spontaneously sealed. Only five
patients under surveillance (20%) have an enlarging sac. There were no ruptured aneurysms or
aneurysm-related deaths and no patients required conversion to open repair.
Conclusions: In this study, a policy of regular surveillance for Type 2 endoleaks was not associated
with any adverse events.We therefore advocate the conservative approach for Type 2 endoleaks.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Endovascular abdominal aortic aneurysm repair (EVAR) was
introduced by Parodi in 1991,1 and since then, the116 2523135; fax: þ44 116
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ty for Vascular Surgery. Publishetechnique has gained popularity due to the significant
advantages over open repair. Several large multicentre
studies have reported a reduction in morbidity and
mortality associated with EVAR.2e4
The UK EVAR1 trial randomised 1082 patients to either
open or endovascular repair and showed a significant
reduction in mortality at 30 days from endovascular repaird by Elsevier Ltd. All rights reserved.
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(4% vs. 7%).2 However, this trial also highlighted a higher
complication rate after EVAR due to stent fracture or
migration, kinking or graft limb thrombosis and endoleak.2,5
The re-intervention rate in EVAR1 was 20% at 4 years and
approximately 50% of these were for endoleak. The annual
cumulative rupture rate after EVAR has been shown to
be 1%.6
One of the most common complications of EVAR is endo-
leak, defined as persistent blood flow within the aneurysm
sac. Endoleak has been classified into five types depending
on the source of origin of the endoleak. Type 1 endoleaks are
due to proximal or distal attachment site leaks, Type 2
endoleaks are due to retrograde flow from aortic branches
and Type 3 endoleaks are due to component separation or
fabric tears. Type 4 endoleaks can only occur within 30 days
of stent-graft insertion and are due to an increase in
graft wall (fabric) porosity. A further category, known as
endotension, has been identified and is described as an
increased intra-sac pressure after EVAR without a visualised
endoleak on delayed contrast computed tomography (CT)
scans.7 In a recent systematic review, the occurrence of Type
1 and Type 2 endoleaks at 12 months was 3.8% and 14%,
respectively.8
Types 1 and 3 endoleaks are often grouped together as
high-pressure leaks, which require urgent attention to
prevent rupture.6 Type 2 endoleaks, arising from aortic side
branches, are the most common type and are regarded as
low-pressure leaks. The natural history of Type 2 endoleaks
is unclear, with some tending to resolve spontaneously,
others persisting without causing clinical symptoms and
a small proportion causing a significant increase in sac
size.9e12
The rupture rate from Type 2 endoleaks appears to be
low and there are only 14 reported cases of ruptured AAA
associated with a Type 2 endoleak in the world literature in
nine studies.9,11,13e20 Data from the EUROSTAR registry on
2463 patients from 87 European centres suggest an inci-
dence of rupture after Type 2 endoleak of 0.52% (one from
191 patients).16 These data also suggested that the rupture
rates were no different in patients with Type 2 endoleak
when compared with patients with no endoleak (0.25%, 5
out of 1975 patients, PZ 0.54).
There is an ongoing debate as to the management of
Type 2 endoleaks, with some authors advocating a conser-
vative approach, some intervening in all cases and others
proposing selective intervention for a significant increase in
sac size (defined as an 8-mm increase in the EUROSTAR
registry).
In Leicester, we have employed a policy of conserva-
tive management for Type 2 endoleaks. The emergence
of more data about the natural history of Type 2 endo-
leaks has reinforced our conservative policy and allowed
us to implement more stringent criteria. Since 2001,
treatment for Type 2 endoleaks has only been performed
if there was a documented increase in sac size of
greater than 5 mm over a 6-month period, or an overall
increase of more than 10 mm from the preoperative
measurements.
The aim of this study was to examine the outcome of
patients with Type 2 endoleaks following EVAR to guide
future management of this complication.Methods
A retrospectiveeprospective study of 369 consecutive
patients who underwent infrarenal EVAR repair at the
Leicester Royal Infirmary between 18 March 1994 and 28
June 2006 was performed. Following EVAR, patients were
followed up at outpatients with clinical examination and
duplex ultrasound scan (DUSS) at 1, 3 and 6 months
postoperatively, and at 6-monthly intervals thereafter.
At the time of DUSS, data were recorded on sac size, the
presence or absence of endoleak and other complications
such as graft limb occlusion. Follow-up data were recorded
on a research database and imaging records were retained
for future reference.
DUSS was performed by B-mode imaging of the aneurysm
sac in transverse and longitudinal planes to identify the graft
and to examine the sac contents (homogeneous or hetero-
geneous) for any regions that look suspicious for endoleak or
show abnormality. The maximum sac diameter was
measured in both antero-posterior and lateral planes (side-
to-side diameter from the coronal position) so that any
changes in sac size could be determined. Colour flow
imaging was the principal method used to examine the sac
for evidence of endoleak. The colour flow scanner controls
were also optimised to detect low-velocity flow from very
small endoleaks. Spectral Doppler recordings were also
taken from any identified endoleak to examine flow char-
acteristics (pendulum flow suggesting a blind-ending endo-
leak, or directional flow that might suggest both inflow and
outflow). Flow within the graft and iliac arteries was also
examined to detect any flow abnormalities, which may
suggest any other graft-related complications such as in-
graft stenosis or kinking. All DUSSs were performed using
a Philips Medical Systems HDI 5000 duplex ultrasound
scanner, Bothell WA, USA and a C5-2 MHz broadband curved-
array transducer (standard colour DUSS with B-mode
imaging, colour flow imaging and spectral Doppler).
In our early experience, clinical decisions regarding
patients in follow-up after EVAR were carried out through
direct discussion between surgeons and radiologists. More
recently, a multidisciplinary team was created (vascular
surgeons, vascular technologists, vascular nurse specialists
and vascular radiologists). Patients found to have an
endoleak on DUSS or where duplex images were suboptimal
and not able to exclude endoleak were discussed in the
above and clinical management plans formulated.
Patients underwent CT angiography if there was an
evidence of a Type 1 endoleak, an indeterminate endoleak
or a sac growth of greater than 5 mm in any 6-month period
or to a size 10 mm greater than the preoperative size.
Type 2 endoleaks were treated by further endovascular
intervention via a transfemoral, translumbar or laparo-
scopic route.
Results
There were 369 elective infrarenal EVARs performed
between 18 March 1994 and 28 June 2006. Seventy-three
(20%) were locally developed aortouniliac (AUI) design; the
remaining 296 were commercial devices e 86 (out of 369;
23%) were Medtronic Talent grafts, 54 (15%) were Gore
Table 2 Type 2 endoleaks.
Device type Number of Type 2 endoleaks (%)
AUI 1 (4)
Medtronic 5 (20)
Gore 10 (40)
Cook 9 (33)
Total 25
Where AUIZ aortouniliac device.
720 H.S. Rayt et al.Excluder, 137 (37%) were Cook Zenith and 19 (5%) were
other commercial devices.
Seventy-seven endoleaks (of varying types) developed in
68 patients (18%; 68 out of 369) (Table 1). There were 41
Type 2 endoleaks in 39 patients but 16 were associated with
another type of leak (14 combined with a Type 1 endoleak
and two combined with a Type 3). Therefore, there were
a total of 25 Type 2 endoleaks in 25 patients, which form
the basis of further analysis (Table 2). Twenty-two patients
were male (88%) and three were female (12%). The mean
age at operation was 71 years with a mean sac size of
6.6 cm. The timing of diagnosis of the Type 2 endoleak was
evenly distributed from 1 month to 12 months and over,
although more endoleaks were seen on discharge scans
than at any other time point (Table 3).
Out of 24 Type 1 endoleaks, 17 occurred within the first
month (71%), compared with seven (29%) detected after 1
month. Only a small number of Type 3 endoleaks were seen
in this study (nZ 4) and all occurred within the first month
after the surgery.
Intervention purely to treat a Type 2 endoleak was
performed in one patient (one out of 25; 4%). This patient
underwent EVAR in 1999 using a Medtronic Talent device.
Pre-discharge scans suggested an endoleak from the left
limb of the graft, which was corrected by an extension
device. Following this, the sac expanded slowly (8.4e
9.1 cm in 29 months) but with no evidence of an endoleak.
Three years postoperatively, a Type 2 endoleak was iden-
tified with sac expansion (10.7 cm). Intervention was
attempted using coil embolisation, thrombin injection into
the aortic sac and laparoscopic clipping of the inferior
mesenteric artery, but all failed. The aneurysm sac
continues to grow and the last measurement was recorded
at 13 cm (CT scan). The patient has remained completely
asymptomatic throughout this period and is unfit for any
other form of intervention.
Six (24%) of the 25 Type 2 endoleaks were associated
with a documented increase in sac size; however, only one
of these (discussed above) met the criteria for consider-
ation of intervention. Five patients continue to remain
under observation for their Type 2 endoleak and one
endoleak sealed spontaneously. Although it is difficult to
estimate due to the differing length of the follow-up
period, the average growth rate was 0.23 mm per month.
Of the remaining 19 patients, 18 (72%) have a stable sac
withno increase in sizeandonewas lost to follow-up (Table4).
After a mean follow-up of 50.4 months, seven out of 18
endoleaks with a stable sac size remain under observation
and 11 have sealed spontaneously (61%).Table 1 Incidence of endoleak (nZ 77 in 68 patients).
Type of endoleak Number of endoleaks (%)
Type 1 24 (31)
Type 2 41 (53)
Type 3 4 (5)
Type 4 1 (1)
Unspecified 7 (9)
Total 77To verify the above data, all the patients who had been
re-admitted after EVAR were identified through the hospital
coding computer system. The notes were then examined to
identify the reason for re-admission. Although only eight
notes were unobtainable, this re-confirmed that there were
no deaths from a ruptured AAA after a Type 2 endoleak.
In summary, only one patient had an increase in sac size
that required intervention. Twelve patients remain under
observation for their endoleak but only five showed an
enlarging sac. Eleven Type 2 endoleaks have sealed spon-
taneously. There were no conversions to open repair and no
ruptured aneurysms among the patients with a Type 2
endoleak.
Two deaths from unknown causes were seen in patients
with Type 2 endoleaks. No deaths were due to aneurysm-
related complications or rupture. The deaths occurred at 22
months and 33 months postoperatively. Our total survival
rate was not assessed during this study but has been
previously published. Five-year follow-up data on 58
consecutive patients who underwent elective EVAR
between 1 July 1994 and 3 October 2000 revealed 13
deaths, none of which was perioperative death (defined as
within 30 days of surgery).21
Discussion
The management of Type 2 endoleaks has evolved with
time. Initially, many of these endoleaks were treated by
radiological or surgical intervention because of the fear of
rupture. Recently, a more conservative approach has been
adopted because many of them seem to be relatively
benign. We have analysed our entire EVAR experience from
1994 to 2006, and during this time, 25 isolated Type 2
endoleaks have been seen. We have intervened only once
despite 24% of these endoleaks having an associated
increase in sac size. We have not experienced any cases ofTable 3 Type 2 endoleaks according to time point
postoperatively.
Discharge 1
month
3
months
6
months
12
months
>12
months
AUI 0 0 0 0 0 1
Medtronic 2 1 0 1 0 1
Gore 2 3 2 1 1 1
Cook 3 1 1 3 1 0
Total 7 5 3 5 2 3
Where AUIZ aortouniliac device.
Table 4 Increase in sac size in association with Type 2 endoleak.
Increase in sac size requiring
intervention
Increase in sac size not
requiring intervention
No increase
in sac size
Unknown
AUI 0 1 0 0
Medtronic 1 0 4 1
Gore 0 3 6 0
Cook 0 1 8 0
Other 0 0 0 0
Total 1 5 18 1
Where AUIZ aortouniliac device.
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performed any open interventions or conversions. Follow-
up data over a mean period of 4 years have shown that 48%
of these Type 2 endoleaks have sealed spontaneously (12
out of 25), 48% remain under observation (12 out of 25) and
one has been lost to follow-up. Currently, only five patients
in our surveillance programme have a Type 2 endoleak and
an enlarging sac.
Although the natural progression of Type 2 endoleaks is
not fully understood, the main concern is rupture. Data
from the EUROSTAR Registry show that the annual cumu-
lative rupture rate from EVAR is approximately 1%.6
However, EUROSTAR also reported (in 2463 patients) that
there was no significant difference in rupture rates after
EVAR in patients with and without a Type 2 endoleak.16
Despite this, many centres continue to intervene for Type 2
endoleaks, particularly if the sac is expanding.
A literature search conducted by the authors of this
article found only 14 reported cases of ruptured AAA from
a Type 2 endoleak in the world literature across nine
studies. This represented a cohort size of 2627 Type 2
endoleaks (14 out of 2627; 0.53%), with only six of these
appearing to have had an increase in sac size.9,13,15,17e19
However, a recent study has found 23 ruptures after Type 2
endoleak,22 although no direct references are given and
some of the data may be from duplicate or updated series.
Other reports from EUROSTAR found that conversion to
open repair or post-EVAR rupture was not associated with
Type 2 endoleaks.12 Similarly, Gelfand showed no associa-
tion between Type 2 endoleak and rupture and also
observed that over 50% of Type 2 endoleaks managed
conservatively for a year resolved spontaneously.23
The ability to detect endoleaks depends on the sensi-
tivity and specificity of the imaging modality. Currently, CT
scanning is the gold standard, but there are concerns about
the radiation load, reactions to contrast medium and the
risk of worsening renal failure.24 Although duplex scanning
is not as sensitive as CT, a recent study has shown that
duplex does detect high-pressure Types 1 and 3 endoleaks
but may miss some Type 2 endoleaks. If Type 2 endoleaks
are benign, even if the sac is expanding, then duplex may
be a more suitable alternative to CT for EVAR follow-up e
with reduced risk and lower costs.25 Whilst DUSS may not be
as sensitive at detecting endoleaks when compared with CT
scan,25 the benefits of detecting clinically non-significant
endoleaks must be weighed against the added burden on
services and subsequent delays in imaging, as well as the
extra radiation load and potential contrast-related issuessuffered by the patient. In this study, any indeterminate
DUSS scans were re-imaged using CT.
Bargellini et al. compared the use of DUSS to CT angio-
gram (CTA) in the post-EVAR assessment of AAA size and
detection and monitoring of endoleaks. There was a high
level of agreement between the findings observed from
DUSS and CTA (k 0.96) in measuring maximum AAA diam-
eter. DUSS detected 76.4% of all endoleaks and of the
remaining endoleaks, only three (4.3%) were clinically
significant with respect to AAA enlargement.26 In a similar
study, specificity of DUSS when compared with that of CTA
for endoleak detection was 67%, mainly due to the large
number of false positives from DUSS, whilst sensitivity for
DUSS was 86%. All clinically significant endoleaks were
identified by both imaging modalities. Despite this, DUSS
only had a positive predictive value of 45%, but encourag-
ingly had a negative predictive value of 94%.27 Another
study has quoted the sensitivity and specificity of DUSS as
33.3% and 92.8%, respectively. However, the positive and
negative predictive values in this study were similar at 71%
and 72%, respectively.28 By contrast, a systematic review
published in 2005 on the same topic concluded that DUSS is
not accurate enough in detecting endoleaks. Although the
study comprised 711 patients and 1355 paired scan results,
these were only from two centres. Data from two studies
included in the article were from unpublished studies. The
pooled sensitivity of DUSS compared with CT was 69%, with
the specificity at 91%.29
Whilst some have criticised the ability of DUSS in
differentiating between Type 1 and Type 2 endoleaks, it
must also be acknowledged that this can also be a problem
with other modalities. Simple Type 2 endoleaks from
branch vessels are normally easy to identify, especially if
they are some distance away from the proximal or distal
attachment sites. It can be more difficult if the endoleak is
towards the bottom or top ends of the sac. Migration is
more difficult to assess using DUSS and is best used when
there has been gross movement, such as the neck ‘falling’
into the sac. For this reason, DUSS is not routinely used to
assess migration, and CT scan is the preferred imaging tool.
Several techniques exist for the treatment of Type 2
endoleaks, including embolisation via a transarterial or
translumbar route, laparoscopic ligation of aortic sac side
branches and vessels and thrombin injection. In a small
series of five patients, Steinmetz et al.10 reviewed both the
translumbar (nZ 4) and transarterial (nZ 4) approaches
and reported no recurrence or aneurysm sac growth in
either group after the procedure. A larger study30
722 H.S. Rayt et al.intervened in 33 Type 2 endoleaks (20 through transarterial
inferior mesenteric artery embolisation and 13 through
translumbar embolisation) and reported failure in 80%
undergoing transarterial embolisation (mean follow-up 396
days) compared with an 8% failure rate with the trans-
lumbar technique (median follow-up 254 days). Similarly,
Stavropoulos reported failure of translumbar embolisation
in three out of nine patients (with 11 Type 2 endoleaks).31
There are very limited data on the effectiveness of
laparoscopic ligation of aortic sac side branches. In total,
three studies describe laparoscopic intervention in five
patients,32e34 and in two patients further laparoscopic
intervention was required to treat recurrence of the
endoleak.33,34
Prophylactic intra-operative embolisation of the inferior
mesenteric artery together with intra-sac thrombin injec-
tion was described by Muthu et al.35 However, there was no
statistically significant difference in the subsequent Type 2
endoleak rate between the intervention group and
a historical control group.
In conclusion, Type 2 endoleaks appear benign even in
the presence of an increasing sac size. The current treat-
ments have a high risk of failure and may not alter overall
outcome.
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